Market Intelligence, Clinical Progress, and High-Purity Reagents for RARA-Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RARA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RARA Recombinant Protein (LBD / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for ligand-binding assays. |
View RARA Products |
| Gene Delivery | RARA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and reporter gene assays. |
View RARA Products |
| Benchmark Ab | Anti-RARA Recombinant Antibody High-affinity positive control for IHC, Western Blot, and ChIP assays. |
View RARA Products |
| Validator | RARA siRNA Set For specific knockdown verification in functional assays. |
View RARA Products |
| Related Target A | RXRA (Retinoid X Receptor Alpha) Essential heterodimerization partner for RARA-mediated transcriptional activation. |
View RXRA Products |
| Related Target B | RARB (Retinoic Acid Receptor Beta) Homolog target for selectivity and off-target toxicity screening. |
View RARB Products |
| Related Target C | RARG (Retinoic Acid Receptor Gamma) Homolog target for counter-screening to prevent mucocutaneous toxicity. |
View RARG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against RAR family (Beta/Gamma) | Recombinant Human RARA, RARB, and RARG proteins available with >95% purity for robust selectivity panels. |
| Heterodimerization assay validation | Co-incubated RARA/RXRA protein complexes verified by size exclusion chromatography (SEC). |
| Lack of Controls | Sequence-verified benchmark antibodies and validated positive control plasmids included. |
| False Positives | Target-specific siRNA pool included for functional knockdown validation. |
Live RARA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Retinoic Acid Receptor Alpha (RARA) is undergoing a major renaissance. Historically defined by the PML-RARA fusion in Acute Promyelocytic Leukemia (APL) treated with ATRA, modern drug discovery is focused on selective non-APL indications. The current race centers on selective RARA agonists (such as Tamibarotene) targeting RARA-overexpressing Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). As resistance to standard hypomethylating agents emerges, the next wave of R&D is prioritizing biomarker-selected patient populations and combination regimens with BCL2 inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Agonist | Syros Pharmaceuticals, Bristol Myers Squibb | RARA-positive AML, MDS | Selectivity assays (Need RARA, RARB, and RARG panel proteins) |
| PROTAC / Degrader | Academic institutions, Biotech startups | Advanced Solid Tumors, Hematologic Malignancies | Degradation kinetics (Need high-purity RARA for ubiquitination assays) |
| Combination Therapies (Agonist + Venetoclax) | AbbVie, Syros Pharmaceuticals | Newly Diagnosed AML | Cell-based reporter assays (Need Lentivirus for RARE-luciferase reporter lines) |